25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

HEPA (Hepion Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Hepion Pharmaceuticals Inc together

I guess you are interested in Hepion Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Hepion Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Hepion Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Hepion Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Hepion Pharmaceuticals Inc

I send you an email if I find something interesting about Hepion Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Hepion Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Hepion Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
25.0%

What is your share worth?

Current worth
$0.34
Expected worth in 1 year
$0.35
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$0.01
Return On Investment
16.2%

For what price can you sell your share?

Current Price per Share
$0.07
Expected price per share
$0.033 - $0.1056
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Hepion Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$0.07
Intrinsic Value Per Share
$-13.43 - $15.41
Total Value Per Share
$-13.09 - $15.74

2.2. Growth of Hepion Pharmaceuticals Inc (5 min.)




Is Hepion Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$3.7m$8.6m-$7.2m-536.6%

How much money is Hepion Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.3m-$7m$3.7m109.2%
Net Profit Margin-2,481.4%-650.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Hepion Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#640 / 853

Most Revenue
#652 / 853

Most Profit
#363 / 853

Most Efficient
#734 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Hepion Pharmaceuticals Inc?

Welcome investor! Hepion Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Hepion Pharmaceuticals Inc.

First you should know what it really means to hold a share of Hepion Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Hepion Pharmaceuticals Inc is $0.066. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hepion Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hepion Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.34. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hepion Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.09-139.4%-0.31-466.9%-0.65-978.9%-0.67-1,009.2%-0.72-1,093.9%-0.54-818.3%
Usd Book Value Change Per Share-0.02-30.0%0.004.0%-0.52-787.2%-0.48-732.1%-0.07-100.9%0.000.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.1%0.000.5%0.0116.9%
Usd Total Gains Per Share-0.02-30.0%0.004.0%-0.52-787.2%-0.48-732.0%-0.07-100.4%0.0117.7%
Usd Price Per Share0.08-0.41-2.94-2.12-1.96-1.74-
Price to Earnings Ratio-0.22--0.41--1.30--0.77--0.74--0.97-
Price-to-Total Gains Ratio-4.05--2.16-25.23-6.66-3.28--21.07-
Price to Book Ratio0.24--4.85-3.76-0.03-0.23--1.02-
Price-to-Total Gains Ratio-4.05--2.16-25.23-6.66-3.28--21.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.066
Number of shares15151
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.07
Usd Total Gains Per Share0.00-0.07
Gains per Quarter (15151 shares)40.44-1,003.85
Gains per Year (15151 shares)161.75-4,015.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1016215219-4034-4025
2032431438-8068-8040
3048547656-12103-12055
4064763875-16137-16070
5080980094-20171-20085
60971962113-24205-24100
7011321124131-28239-28115
8012941286150-32274-32130
9014561448169-36308-36145
10016181610188-40342-40160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%2.046.00.04.2%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%12.028.00.030.0%15.033.00.031.3%
Dividend per Share0.00.04.00.0%2.00.010.016.7%8.00.012.040.0%10.00.030.025.0%11.00.037.022.9%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%13.027.00.032.5%17.031.00.035.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Hepion Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0200.003-841%-0.520+2527%-0.483+2343%-0.067+237%0.001-3719%
Book Value Per Share--0.3350.121+177%0.786-57%1.613-79%3.844-91%2.214-85%
Current Ratio--7.6004.041+88%4.561+67%4.940+54%8.809-14%6.358+20%
Debt To Asset Ratio--0.1570.951-83%0.472-67%0.545-71%0.384-59%0.525-70%
Debt To Equity Ratio--0.1870.202-8%0.961-81%0.480-61%0.361-48%1.170-84%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%0.011-100%
Enterprise Value--3122113.7604104262.440-24%33198310.408-91%30932215.166-90%48743460.637-94%33428153.866-91%
Eps---0.092-0.308+235%-0.646+602%-0.666+624%-0.722+684%-0.540+487%
Ev To Ebitda Ratio---0.581-0.376-35%-1.077+85%-0.892+53%-1.641+182%-1.987+242%
Free Cash Flow Per Share---0.121-0.139+15%-0.792+552%-0.573+372%-0.606+399%-0.467+285%
Free Cash Flow To Equity Per Share---0.1350.035-488%-0.648+380%-0.444+229%0.014-1042%0.044-405%
Gross Profit Margin--1.0001.0000%1.0030%1.0010%1.0010%1.0000%
Intrinsic Value_10Y_max--15.409----------
Intrinsic Value_10Y_min---13.427----------
Intrinsic Value_1Y_max---1.377----------
Intrinsic Value_1Y_min---2.146----------
Intrinsic Value_3Y_max---1.911----------
Intrinsic Value_3Y_min---5.793----------
Intrinsic Value_5Y_max--0.239----------
Intrinsic Value_5Y_min---8.694----------
Market Cap724435.800-25%906249.7604534760.190-80%32215714.908-97%23301463.083-96%21473574.637-96%19123503.741-95%
Net Profit Margin----24.8140%-6.5020%-10.4390%-6.2630%-3.1320%
Operating Margin----0%-13.2570%-4.4190%-2.6510%-1.3260%
Operating Ratio---5.204-100%11.807-100%5.670-100%3.402-100%1.701-100%
Pb Ratio0.197-21%0.239-4.851+2132%3.763-94%0.034+602%0.229+4%-1.015+525%
Pe Ratio-0.179+18%-0.217-0.405+87%-1.303+500%-0.774+256%-0.739+240%-0.966+345%
Price Per Share0.066-21%0.0800.413-81%2.935-97%2.123-96%1.956-96%1.742-95%
Price To Free Cash Flow Ratio-0.136+18%-0.165-0.767+366%-1.088+560%-0.872+429%-0.853+418%-9.923+5924%
Price To Total Gains Ratio-3.338+18%-4.046-2.155-47%25.229-116%6.658-161%3.280-223%-21.066+421%
Quick Ratio--4.9332.651+86%2.568+92%3.104+59%6.858-28%5.302-7%
Return On Assets---0.231-0.867+275%-0.466+101%-0.518+124%-0.361+56%-0.352+52%
Return On Equity---0.275-0.460+68%-0.913+232%-0.555+102%-0.398+45%-0.595+117%
Total Gains Per Share---0.0200.003-841%-0.520+2527%-0.483+2343%-0.066+235%0.012-269%
Usd Book Value--3796938.0001355744.500+180%8630708.250-56%17715520.917-79%42193488.100-91%24309384.100-84%
Usd Book Value Change Per Share---0.0200.003-841%-0.520+2527%-0.483+2343%-0.067+237%0.001-3719%
Usd Book Value Per Share--0.3350.121+177%0.786-57%1.613-79%3.844-91%2.214-85%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%0.011-100%
Usd Enterprise Value--3122113.7604104262.440-24%33198310.408-91%30932215.166-90%48743460.637-94%33428153.866-91%
Usd Eps---0.092-0.308+235%-0.646+602%-0.666+624%-0.722+684%-0.540+487%
Usd Free Cash Flow---1375360.000-1540897.000+12%-8695393.750+532%-6296673.417+358%-6649835.650+383%-5129611.280+273%
Usd Free Cash Flow Per Share---0.121-0.139+15%-0.792+552%-0.573+372%-0.606+399%-0.467+285%
Usd Free Cash Flow To Equity Per Share---0.1350.035-488%-0.648+380%-0.444+229%0.014-1042%0.044-405%
Usd Market Cap724435.800-25%906249.7604534760.190-80%32215714.908-97%23301463.083-96%21473574.637-96%19123503.741-95%
Usd Price Per Share0.066-21%0.0800.413-81%2.935-97%2.123-96%1.956-96%1.742-95%
Usd Profit---1042572.000-3390465.250+225%-7091398.000+580%-7052165.500+576%-7769364.500+645%-5503069.000+428%
Usd Revenue---15379.000-100%27432.500-100%14270.500-100%8562.300-100%4281.150-100%
Usd Total Gains Per Share---0.0200.003-841%-0.520+2527%-0.483+2343%-0.066+235%0.012-269%
 EOD+3 -5MRQTTM+17 -17YOY+22 -153Y+21 -165Y+17 -2010Y+15 -22

3.3 Fundamental Score

Let's check the fundamental score of Hepion Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.179
Price to Book Ratio (EOD)Between0-10.197
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.933
Current Ratio (MRQ)Greater than17.600
Debt to Asset Ratio (MRQ)Less than10.157
Debt to Equity Ratio (MRQ)Less than10.187
Return on Equity (MRQ)Greater than0.15-0.275
Return on Assets (MRQ)Greater than0.05-0.231
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Hepion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.830
Ma 20Greater thanMa 500.056
Ma 50Greater thanMa 1000.061
Ma 100Greater thanMa 2000.147
OpenGreater thanClose0.072
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Fundamental data was last updated by Penke on 2025-09-04 01:02:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Hepion Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Hepion Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,481.4%+2,481.4%
TTM-2,481.4%YOY-650.2%-1,831.2%
TTM-2,481.4%5Y-626.3%-1,855.1%
5Y-626.3%10Y-313.2%-313.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM-2,481.4%-171.0%-2,310.4%
YOY-650.2%-210.0%-440.2%
3Y-1,043.9%-289.9%-754.0%
5Y-626.3%-381.1%-245.2%
10Y-313.2%-520.3%+207.1%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Hepion Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Hepion Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -23.1% Return on Assets means thatΒ Hepion Pharmaceuticals Inc generatedΒ $-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hepion Pharmaceuticals Inc:

  • The MRQ is -23.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -86.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.1%TTM-86.7%+63.5%
TTM-86.7%YOY-46.6%-40.1%
TTM-86.7%5Y-36.1%-50.5%
5Y-36.1%10Y-35.2%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.1%-11.9%-11.2%
TTM-86.7%-11.9%-74.8%
YOY-46.6%-11.2%-35.4%
3Y-51.8%-12.0%-39.8%
5Y-36.1%-11.7%-24.4%
10Y-35.2%-13.8%-21.4%
4.3.1.3. Return on Equity

Shows how efficient Hepion Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Hepion Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -27.5% Return on Equity means Hepion Pharmaceuticals Inc generated $-0.27Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hepion Pharmaceuticals Inc:

  • The MRQ is -27.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -46.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.5%TTM-46.0%+18.6%
TTM-46.0%YOY-91.3%+45.3%
TTM-46.0%5Y-39.8%-6.2%
5Y-39.8%10Y-59.5%+19.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.5%-14.2%-13.3%
TTM-46.0%-15.2%-30.8%
YOY-91.3%-15.3%-76.0%
3Y-55.5%-16.9%-38.6%
5Y-39.8%-17.5%-22.3%
10Y-59.5%-19.6%-39.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Hepion Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Hepion Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit Hepion Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Hepion Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,325.7%+1,325.7%
TTM-5Y-265.1%+265.1%
5Y-265.1%10Y-132.6%-132.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM--280.2%+280.2%
YOY-1,325.7%-268.7%-1,057.0%
3Y-441.9%-281.5%-160.4%
5Y-265.1%-350.8%+85.7%
10Y-132.6%-530.7%+398.1%
4.3.2.2. Operating Ratio

Measures how efficient Hepion Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.204-5.204
TTM5.204YOY11.807-6.603
TTM5.2045Y3.402+1.802
5Y3.40210Y1.701+1.701
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.952-1.952
TTM5.2042.974+2.230
YOY11.8073.047+8.760
3Y5.6703.835+1.835
5Y3.4024.924-1.522
10Y1.7016.864-5.163
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Hepion Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 7.60Β means the company has $7.60 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 7.600. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.041. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.600TTM4.041+3.559
TTM4.041YOY4.561-0.520
TTM4.0415Y8.809-4.768
5Y8.80910Y6.358+2.451
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6003.480+4.120
TTM4.0413.790+0.251
YOY4.5614.104+0.457
3Y4.9404.609+0.331
5Y8.8095.764+3.045
10Y6.3586.154+0.204
4.4.3.2. Quick Ratio

Measures if Hepion Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Hepion Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 4.93Β means the company can pay off $4.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 4.933. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.651. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.933TTM2.651+2.281
TTM2.651YOY2.568+0.083
TTM2.6515Y6.858-4.207
5Y6.85810Y5.302+1.556
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9332.938+1.995
TTM2.6513.291-0.640
YOY2.5683.928-1.360
3Y3.1044.393-1.289
5Y6.8585.837+1.021
10Y5.3026.549-1.247
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Hepion Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Hepion Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Hepion Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16Β means that Hepion Pharmaceuticals Inc assets areΒ financed with 15.7% credit (debt) and the remaining percentage (100% - 15.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.157. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.951. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.157TTM0.951-0.794
TTM0.951YOY0.472+0.479
TTM0.9515Y0.384+0.567
5Y0.38410Y0.525-0.141
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1570.339-0.182
TTM0.9510.359+0.592
YOY0.4720.334+0.138
3Y0.5450.341+0.204
5Y0.3840.349+0.035
10Y0.5250.379+0.146
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Hepion Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Hepion Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 18.7% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hepion Pharmaceuticals Inc:

  • The MRQ is 0.187. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.202. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.187TTM0.202-0.015
TTM0.202YOY0.961-0.759
TTM0.2025Y0.361-0.159
5Y0.36110Y1.170-0.809
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1870.391-0.204
TTM0.2020.436-0.234
YOY0.9610.436+0.525
3Y0.4800.461+0.019
5Y0.3610.461-0.100
10Y1.1700.514+0.656
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Hepion Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Hepion Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.22 means the investor is paying $-0.22Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hepion Pharmaceuticals Inc:

  • The EOD is -0.179. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.217. Based on the earnings, the company is expensive. -2
  • The TTM is -0.405. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.179MRQ-0.217+0.038
MRQ-0.217TTM-0.405+0.188
TTM-0.405YOY-1.303+0.898
TTM-0.4055Y-0.739+0.333
5Y-0.73910Y-0.966+0.227
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.179-2.539+2.360
MRQ-0.217-2.361+2.144
TTM-0.405-2.657+2.252
YOY-1.303-3.749+2.446
3Y-0.774-3.883+3.109
5Y-0.739-6.353+5.614
10Y-0.966-7.102+6.136
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hepion Pharmaceuticals Inc:

  • The EOD is -0.136. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.165. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.767. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.136MRQ-0.165+0.029
MRQ-0.165TTM-0.767+0.603
TTM-0.767YOY-1.088+0.321
TTM-0.7675Y-0.853+0.086
5Y-0.85310Y-9.923+9.069
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.136-3.411+3.275
MRQ-0.165-2.951+2.786
TTM-0.767-3.614+2.847
YOY-1.088-4.421+3.333
3Y-0.872-5.258+4.386
5Y-0.853-8.587+7.734
10Y-9.923-9.639-0.284
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Hepion Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.24 means the investor is paying $0.24Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Hepion Pharmaceuticals Inc:

  • The EOD is 0.197. Based on the equity, the company is cheap. +2
  • The MRQ is 0.239. Based on the equity, the company is cheap. +2
  • The TTM is -4.851. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.197MRQ0.239-0.042
MRQ0.239TTM-4.851+5.089
TTM-4.851YOY3.763-8.613
TTM-4.8515Y0.229-5.079
5Y0.22910Y-1.015+1.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.1972.206-2.009
MRQ0.2392.027-1.788
TTM-4.8512.194-7.045
YOY3.7632.425+1.338
3Y0.0342.571-2.537
5Y0.2293.805-3.576
10Y-1.0154.462-5.477
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Hepion Pharmaceuticals Inc.

4.8.1. Institutions holding Hepion Pharmaceuticals Inc

Institutions are holding 0.203% of the shares of Hepion Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Sabby Management LLC7.19961.05878366158366150
2025-06-30XTX Topco Ltd0.14940.000117361173610
2025-03-31HRT FINANCIAL LLC0.141016387163870
2025-03-31Citadel Advisors Llc0.1341015581155810
2025-03-31BlackRock Inc0.014301658-1-0.0603
2025-03-31PNC Financial Services Group Inc0.0013015621.2987
2025-03-31FMR Inc0.000901001000
2025-03-31SBI Securities Co Ltd0.0003032301500
2025-03-31Morgan Stanley - Brokerage Accounts0.0003030300
2025-03-31Group One Trading, LP00440
2025-03-31Federation des caisses Desjardins du Quebec00300
2025-03-31Hanson Mcclain Inc00220
2025-03-31Advisor Group Holdings, Inc.00220
2025-03-31Bank of America Corp0021100
2025-03-31State Street Corp000-314-100
2025-03-31Susquehanna International Group, LLP000-521-100
2025-06-30Tower Research Capital LLC000-110-100
2025-03-31UBS Group AG000-281-100
2025-03-31Renaissance Technologies Corp000-347-100
2025-03-31Vanguard Group Inc000-1005-100
Total 7.64121.0588887933+883536+99.5%

4.9.2. Funds holding Hepion Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.000107687680
2025-03-31SSgA U.S. Total Market Index Strategy0.000101400
Total 0.00020782+768+98.2%

5.3. Insider Transactions

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-27Peter WijngaardBUY50152.5
2023-11-24Peter WijngaardBUY50154.5
2023-09-19Peter WijngaardBUY20282
2023-09-18Robert T FosterBUY32280
2023-09-15Peter WijngaardBUY40280
2023-09-15Robert T FosterBUY32270
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets4,505
Total Liabilities709
Total Stockholder Equity3,797
 As reported
Total Liabilities 709
Total Stockholder Equity+ 3,797
Total Assets = 4,505

Assets

Total Assets4,505
Total Current Assets4,505
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 2,924
Other Current Assets 1,581
Total Current Assets  (as reported)4,505
Total Current Assets  (calculated)4,505
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities593
Long-term Liabilities116
Total Stockholder Equity3,797
Total Current Liabilities
Short-term Debt 372
Short Long Term Debt 372
Accounts payable 173
Other Current Liabilities 48
Total Current Liabilities  (as reported)593
Total Current Liabilities  (calculated)965
+/- 372
Long-term Liabilities
Long-term Liabilities  (as reported)116
Long-term Liabilities  (calculated)0
+/- 116
Total Stockholder Equity
Common Stock1
Retained Earnings -244,968
Accumulated Other Comprehensive Income 8
Other Stockholders Equity 247,061
Total Stockholder Equity (as reported)3,797
Total Stockholder Equity (calculated)2,102
+/- 1,695
Other
Capital Stock1,696
Cash and Short Term Investments 2,924
Common Stock Shares Outstanding 11,328
Liabilities and Stockholders Equity 4,505
Net Debt -2,553
Net Invested Capital 2,473
Net Working Capital 3,913
Short Long Term Debt Total 372



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
76
9
2,643
2,001
1,005
8,965
9,500
5,377
2,854
10,646
6,750
13,107
8,816
16,068
11,760
18,385
14,121
11,253
9,396
7,975
14,381
8,189
7,905
23,339
21,073
20,433
23,270
24,084
20,364
48,645
123,757
119,753
111,602
103,552
95,855
83,566
69,697
60,244
49,496
36,502
25,003
18,094
15,989
6,010
3,715
1,614
6,319
4,505
4,5056,3191,6143,7156,01015,98918,09425,00336,50249,49660,24469,69783,56695,855103,552111,602119,753123,75748,64520,36424,08423,27020,43321,07323,3397,9058,18914,3817,9759,39611,25314,12118,38511,76016,0688,81613,1076,75010,6462,8545,3779,5008,9651,0052,0012,643976
   > Total Current Assets 
76
9
2,628
1,982
893
8,851
9,362
5,244
2,720
10,518
6,626
7,895
3,613
10,859
6,559
13,193
8,937
6,062
4,149
2,741
9,155
2,968
1,913
17,389
15,185
14,389
17,308
18,169
14,352
42,634
117,745
113,673
105,500
97,452
89,774
79,534
65,670
56,496
45,806
32,762
21,269
17,488
15,430
5,482
3,530
1,614
6,319
4,505
4,5056,3191,6143,5305,48215,43017,48821,26932,76245,80656,49665,67079,53489,77497,452105,500113,673117,74542,63414,35218,16917,30814,38915,18517,3891,9132,9689,1552,7414,1496,0628,93713,1936,55910,8593,6137,8956,62610,5182,7205,2449,3628,8518931,9822,628976
       Cash And Cash Equivalents 
76
3
2,510
1,818
735
8,792
8,901
4,563
1,791
9,832
5,957
7,404
3,028
10,552
6,137
12,983
8,779
5,954
3,998
2,580
9,032
2,832
1,683
17,149
14,864
13,923
16,048
17,562
13,711
40,727
115,449
110,091
98,731
91,349
79,223
71,708
59,145
51,189
42,993
30,522
19,284
14,786
13,106
2,115
1,497
406
4,586
2,924
2,9244,5864061,4972,11513,10614,78619,28430,52242,99351,18959,14571,70879,22391,34998,731110,091115,44940,72713,71117,56216,04813,92314,86417,1491,6832,8329,0322,5803,9985,9548,77912,9836,13710,5523,0287,4045,9579,8321,7914,5638,9018,7927351,8182,510376
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
436
489
0
0
0
0
600
0
0
0
000600000048943600000000000000000000000000000000000000
       Other Current Assets 
0
6
117
164
158
60
460
681
929
685
670
491
585
307
421
210
159
216
151
161
123
136
230
240
321
0
1,260
607
641
1,907
2,296
3,582
6,769
0
10,552
7,826
6,524
0
2,813
2,241
1,985
0
2,325
3,367
1,433
0
1,732
1,581
1,5811,73201,4333,3672,32501,9852,2412,81306,5247,82610,55206,7693,5822,2961,9076416071,26003212402301361231611512161592104213075854916706859296814606015816411760
   > Long-term Assets 
0
0
16
19
111
113
138
133
134
129
123
5,212
5,203
5,209
5,201
5,192
5,184
5,191
5,247
5,234
5,226
5,221
5,991
5,950
5,889
6,044
5,963
5,915
6,011
6,011
6,012
6,080
6,101
6,101
6,081
4,032
4,028
3,748
3,690
3,740
3,734
607
559
528
185
0
0
0
0001855285596073,7343,7403,6903,7484,0284,0326,0816,1016,1016,0806,0126,0116,0115,9155,9636,0445,8895,9505,9915,2215,2265,2345,2475,1915,1845,1925,2015,2095,2035,212123129134133138113111191600
       Property Plant Equipment 
0
0
16
15
56
62
87
81
83
77
72
81
74
80
72
68
62
57
46
42
37
32
790
749
700
855
773
725
660
665
666
599
545
456
368
275
183
132
64
61
284
242
182
151
118
0
0
0
0001181511822422846164132183275368456545599666665660725773855700749790323742465762687280748172778381876256151600
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
1,871
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,8711,87100000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
3,190
0
0
0
0
0
0
0
00000003,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,1903,19000000000000
       Other Assets 
0
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,263
0
3,322
3,318
3,318
141
3,331
3,318
3,318
3,318
3,318
3,481
4,032
285
420
495
583
652
568
0
426
0
0
0
0
0
0
0
0
0
0
000000000042605686525834954202854,0323,4813,3183,3183,3183,3183,3311413,3183,3183,32203,26300000000000000060
> Total Liabilities 
399
499
9,986
4,934
465
361
1,616
1,938
4,215
5,662
5,454
11,789
11,812
10,190
12,145
9,327
9,128
2,604
6,345
8,727
9,727
6,214
7,259
5,310
4,847
4,250
4,502
5,792
7,491
8,125
6,182
9,032
8,959
10,557
9,219
16,246
10,438
10,389
12,344
10,129
8,844
10,814
8,468
2,448
4,122
3,477
2,422
709
7092,4223,4774,1222,4488,46810,8148,84410,12912,34410,38910,43816,2469,21910,5578,9599,0326,1828,1257,4915,7924,5024,2504,8475,3107,2596,2149,7278,7276,3452,6049,1289,32712,14510,19011,81211,7895,4545,6624,2151,9381,6163614654,9349,986499399
   > Total Current Liabilities 
399
499
260
459
465
361
1,616
1,938
4,215
3,761
4,289
5,084
5,162
3,224
2,474
2,945
2,811
2,604
2,563
5,000
5,653
2,850
3,457
1,798
1,505
1,252
1,536
2,603
3,956
4,662
2,867
7,102
7,082
8,206
6,260
13,377
7,489
7,886
9,800
7,674
6,402
5,290
2,574
976
2,716
3,144
936
593
5939363,1442,7169762,5745,2906,4027,6749,8007,8867,48913,3776,2608,2067,0827,1022,8674,6623,9562,6031,5361,2521,5051,7983,4572,8505,6535,0002,5632,6042,8112,9452,4743,2245,1625,0844,2893,7614,2151,9381,616361465459260499399
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
10
0
0
0
0
0
0
0
2,000
2,070
1,440
2,093
1,171
713
0
546
549
551
280
599
572
571
0
495
354
211
0
107
0
112
0
134
154
2,224
0
526
372
37252602,224154134011201070211354495057157259928055154954607131,1712,0931,4402,0702,00000000001000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,903
790
330
0
0
0
0
0
177
0
0
0
0
0
0
0
0
0
0
0
0
0
2,106
2,900
526
372
3725262,9002,1060000000000000177000003307901,9030000000000000000000000
       Accounts payable 
28
56
188
244
213
114
1,313
1,481
3,196
3,162
3,441
4,252
4,397
2,303
1,563
1,627
1,483
1,557
1,732
2,079
2,216
748
707
283
675
492
850
972
1,297
3,722
1,662
3,087
1,794
2,446
2,383
8,912
2,627
2,666
3,168
4,191
3,006
2,349
1,497
447
186
220
243
173
1732432201864471,4972,3493,0064,1913,1682,6662,6278,9122,3832,4461,7943,0871,6623,7221,2979728504926752837077482,2162,0791,7321,5571,4831,6271,5632,3034,3974,2523,4413,1623,1961,4811,3131142132441885628
       Other Current Liabilities 
371
443
72
215
251
247
303
457
1,019
599
847
821
765
921
911
1,318
1,328
1,047
831
920
1,367
661
657
345
117
0
65
992
1,587
660
606
3,414
4,718
2,988
3,382
4,112
4,652
366
6,632
3,483
3,284
386
943
221
306
0
166
48
4816603062219433863,2843,4836,6323664,6524,1123,3822,9884,7183,4146066601,5879926501173456576611,3679208311,0471,3281,3189119217658218475991,01945730324725121572443371
   > Long-term Liabilities 
28
56
9,726
4,475
213
114
1,313
1,481
3,196
1,901
1,166
6,706
6,650
6,966
9,672
6,382
6,318
4,950
3,782
3,727
4,074
3,364
3,802
3,512
3,342
2,998
2,966
3,188
3,535
3,463
3,315
1,930
1,876
2,351
2,959
2,869
2,949
2,503
2,544
2,455
2,442
5,523
5,894
1,473
1,406
333
1,487
116
1161,4873331,4061,4735,8945,5232,4422,4552,5442,5032,9492,8692,9592,3511,8761,9303,3153,4633,5353,1882,9662,9983,3423,5123,8023,3644,0743,7273,7824,9506,3186,3829,6726,9666,6506,7061,1661,9013,1961,4811,3131142134,4759,7265628
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
177
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000017700000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,727
4,074
3,364
3,259
3,010
2,881
2,454
2,494
2,594
3,000
2,991
3,014
1,764
1,777
2,301
2,959
2,869
2,949
2,503
0
0
0
0
0
0
0
0
0
0
00000000002,5032,9492,8692,9592,3011,7771,7643,0142,9913,0002,5942,4942,4542,8813,0103,2593,3644,0743,7270000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,190
3,190
3,190
3,203
3,190
3,190
3,190
3,190
3,190
3,190
3,190
414
413
0
0
0
0
0
0
409
409
0
0
0
0
0
0
0
0
000000004094090000004134143,1903,1903,1903,1903,1903,1903,1903,2033,1903,1903,1900000000000000000000
> Total Stockholder Equity
-323
-490
-7,342
-2,933
540
8,604
7,884
3,439
-1,361
4,984
1,295
1,318
-2,996
5,878
-385
9,058
4,993
3,703
3,052
-752
4,654
1,975
645
18,029
16,227
16,183
18,768
18,292
12,873
40,520
117,575
110,721
102,643
92,995
86,636
67,320
59,259
49,856
37,152
26,373
16,159
7,281
7,521
3,562
-407
-1,863
3,896
3,797
3,7973,896-1,863-4073,5627,5217,28116,15926,37337,15249,85659,25967,32086,63692,995102,643110,721117,57540,52012,87318,29218,76816,18316,22718,0296451,9754,654-7523,0523,7034,9939,058-3855,878-2,9961,3181,2954,984-1,3613,4397,8848,604540-2,933-7,342-490-323
   Common Stock
1
1
2
2
2
2
2
2
2
3
3
3
6
6
6
8
8
1
8
1
2
0
2
0
0
0
1
1
1
3
8
8
8
8
8
8
8
8
0
0
0
0
1
1
1
0
1
1
110111000088888888311100020218188666333222222211
   Retained Earnings -244,968-243,926-237,820-236,272-231,406-227,481-224,627-213,568-203,041-188,961-175,701-168,890-160,342-140,431-133,501-127,095-117,828-110,163-104,105-99,150-92,349-87,409-83,186-81,288-79,469-78,448-76,464-73,891-73,734-69,705-67,015-65,278-59,504-61,554-53,935-49,429-44,612-39,406-35,489-32,458-27,614-22,239-14,841-6,892-5,421-9,802-491-323
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77,462
76,651
77,327
95,773
95,798
97,651
104,459
0
0
142,911
226,022
226,834
0
0
0
0
0
0
223,944
227,806
0
0
0
0
0
0
0
0
00000000227,806223,944000000226,834226,022142,91100104,45997,65195,79895,77377,32776,65177,46200000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
-1
0
2,458
2,486
7,429
12,742
16,420
17,351
17,395
26,770
26,999
32,227
44,597
58,575
60,122
67,514
69,223
69,677
71,708
72,126
77,462
76,653
77,327
95,773
95,798
3
104,459
108,924
110,310
142,911
226,022
226,834
228,023
0
225,354
225,989
226,535
-90
224,489
227,806
228,125
0
233,298
233,326
234,224
0
246,117
247,061
247,061246,1170234,224233,326233,2980228,125227,806224,489-90226,535225,989225,3540228,023226,834226,022142,911110,310108,924104,459395,79895,77377,32776,65377,46272,12671,70869,67769,22367,51460,12258,57544,59732,22726,99926,77017,39517,35116,42012,7427,4292,4862,4580-1



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-31
Gross Profit-31-31
 
Operating Income (+$)
Gross Profit-31
Operating Expense-19,347
Operating Income-19,347-19,378
 
Operating Expense (+$)
Research Development11,847
Selling General Administrative7,499
Selling And Marketing Expenses0
Operating Expense19,34719,346
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,247
Other Finance Cost-0
Net Interest Income-1,247
 
Pretax Income (+$)
Operating Income-19,347
Net Interest Income-1,247
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-16,162-22,532
EBIT - interestExpense = -18,656
-16,161
-11,945
Interest Expense1,247
Earnings Before Interest and Taxes (EBIT)-17,409-14,915
Earnings Before Interest and Taxes (EBITDA)-19,347
 
After tax Income (+$)
Income Before Tax-16,162
Tax Provision--2,969
Net Income From Continuing Ops-13,192-13,193
Net Income-13,192
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses19,347
Total Other Income/Expenses Net3,1851,247
 

Technical Analysis of Hepion Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hepion Pharmaceuticals Inc. The general trend of Hepion Pharmaceuticals Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hepion Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Hepion Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hepion Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.082 < 0.0953 < 0.1056.

The bearish price targets are: 0.033.

Know someone who trades $HEPA? Share this with them.πŸ‘‡

Hepion Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hepion Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hepion Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hepion Pharmaceuticals Inc. The current macd is -0.00021353.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hepion Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hepion Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hepion Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Hepion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartHepion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hepion Pharmaceuticals Inc. The current adx is 40.98.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hepion Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Hepion Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hepion Pharmaceuticals Inc. The current sar is 0.08383118.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hepion Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hepion Pharmaceuticals Inc. The current rsi is 52.83. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Hepion Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartHepion Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hepion Pharmaceuticals Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hepion Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Hepion Pharmaceuticals Inc Daily Stochastic Oscillator ChartHepion Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hepion Pharmaceuticals Inc. The current cci is 76.97.

Hepion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartHepion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hepion Pharmaceuticals Inc. The current cmo is 16.49.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Hepion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartHepion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hepion Pharmaceuticals Inc. The current willr is -38.0952381.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hepion Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hepion Pharmaceuticals Inc Daily Williams %R ChartHepion Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hepion Pharmaceuticals Inc. The current atr is 0.01638395.

Hepion Pharmaceuticals Inc Daily Average True Range (ATR) ChartHepion Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hepion Pharmaceuticals Inc. The current obv is 536,727,506.

Hepion Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartHepion Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hepion Pharmaceuticals Inc. The current mfi is 73.50.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Hepion Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartHepion Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hepion Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-06-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-04STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Hepion Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hepion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.830
Ma 20Greater thanMa 500.056
Ma 50Greater thanMa 1000.061
Ma 100Greater thanMa 2000.147
OpenGreater thanClose0.072
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Hepion Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Hepion Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hepion Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hepion Pharmaceuticals Inc

I send you an email if I find something interesting about Hepion Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Hepion Pharmaceuticals Inc.

Receive notifications about Hepion Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.